News

Nov 07, 2022 Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 01, 2022 Atossa Therapeutics, Inc. to Acquire Stake in Privately Held Dynamic Cell Therapies as Part of Overall CAR-T Strategy

Oct 25, 2022 Atossa Therapeutics, Inc. Announces Appointment of Pharma Industry Veteran Richard Graydon, M.D., Ph.D.

Oct 24, 2022 Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate its Phase 2 Study of Neoadjuvant (Z)-endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer

Sep 07, 2022 Atossa Therapeutics, Inc. to Attend the 24th Annual H.C. Wainwright Global Investment Conference

Aug 22, 2022 Registration Now Open for Tribe Public's Webinar Event "The Important Role For Inhalation Therapy In Oncology" Featuring The Management Team From Atossa Therapeutics on August 25, 2022

Aug 18, 2022 Atossa Therapeutics Appoints Dr. Paul Wabnitz to Its Scientific Advisory Board

Aug 08, 2022 Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Jul 28, 2022 Dosing Completed in Part C of Atossa's Phase 1/2a Study of AT-H201 in Healthy Volunteers

Jun 02, 2022 Atossa Therapeutics Appoints Biotech Industry Communications Veteran Charles Butler as Vice President, Investor Relations and Public Relations

<< < > >>